title: Anti-HER2/Neu passive-aggressive immunotherapy.
abstract: Preclinical studies have established that CD8+T cells are necessary for efficient immunotherapeutic regimens targetingv-erb-b2avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2, best known as HER2/Neu). Recently, we extended upon these findings by demonstrating that anti-HER2/Neu therapy also requires CD4+T cells and CD40/CD40L signaling within the tumor microenvironment. Our results add to mounting evidence demonstrating that adaptive immunity is crucial to the efficacy of conventional and targeted anticancer chemotherapeutics.
authors.affiliation: Department of Melanoma Medical Oncology-Research; MD Anderson Cancer Center; Houston, TX USA.
authors.forename: Eric D
authors.initials: ED
authors.lastname: Mortenson
authors.affiliation: Department of Pathology and Committee on Immunology; University of Chicago; Chicago, IL USA.
authors.forename: Yang-Xin
authors.initials: YX
authors.lastname: Fu
keywords: CD4; CD40; CD40L; CD8; HER2; Herceptin; adaptive immunity; antibody; immunotherapy; neu